ReviewAdvances in cancer research2014
Cerenkov imaging.
Review in Advances in cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Surgical radioguidance with beta-emitting radionuclides; challenges and possibilities: A position paper by the EANM.European journal of nuclear medicine and molecular imaging · 2024Guideline
- Illuminating the metabolic sink: Optical probes for in vivo thermogenic fat imaging.Materials today. Bio · 2026Review
- Compton Imaging of Ac-225 In Pre-clinical Phantoms With a 3D-positioning CZT Camera.IEEE transactions on radiation and plasma medical sciences · 2026Article
- Early diagnosis of colorectal cancer using Cerenkov luminescence endoscopy: a pilot trial involving humans for the first time.Theranostics · 2026Observational
- Construction of a high-sensitivity Cherenkov luminescence endoscopy system for the detection of gastrointestinal cancers.EJNMMI research · 2025Article
- Technologies and techniques to improve precision in breast conserving surgery.Journal of surgical oncology · 2025Review
- ROS-activatable Prodrug of Doxazolidine as Novel Cancer Therapy Paradigm.Advanced therapeutics · 2024Article
- Current clinical applications of Cerenkov luminescence for intraoperative molecular imaging.European journal of nuclear medicine and molecular imaging · 2024Review
- Luminescence Probes in Bio-Applications: From Principle to Practice.Biosensors · 2024Review
- The current status and future prospects for molecular imaging-guided precision surgery.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Radiation Protection and Occupational Exposure onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Nuclear-medicine probes: Where we are and where we are going.Medical physics · 2022Review
- Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location.Nature biomedical engineering · 2022Observational
- Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2022Review
- How molecular imaging will enable robotic precision surgery : The role of artificial intelligence, augmented reality, and navigation.European journal of nuclear medicine and molecular imaging · 2021Review
- Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging-utilization of a short-pass filter to reduce technical pitfalls.Translational andrology and urology · 2021Article
- Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers.Molecular pharmaceutics · 2021Article
- Surgical Advances in Osteosarcoma.Cancers · 2021Review
- IntraoperativeJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cerenkov luminescence (CL) has been used recently in a plethora of medical applications like imaging and therapy with clinically relevant medical isotopes. The range of medical isotopes used is fairly large and expanding. The generation of in vivo light is useful since it circumvents depth limitations for excitation light. Cerenkov luminescence imaging (CLI) is much cheaper in terms of infrastructure than positron emission tomography (PET) and is particularly useful for imaging of superficial structures. Imaging can basically be done using a sensitive camera optimized for low-light conditions, and it has a better resolution than any other nuclear imaging modality. CLI has been shown to effectively diagnose disease with regularly used PET isotope ((18)F-FDG) in clinical setting. Cerenkov luminescence tomography, Cerenkov luminescence endoscopy, and intraoperative Cerenkov imaging have also been explored with positive conclusions expanding the current range of applications. Cerenkov has also been used to improve PET imaging resolution since the source of both is the radioisotope being used. Smart imaging agents have been designed based on modulation of the Cerenkov signal using small molecules and nanoparticles giving better insight of the tumor biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.